ONC Insider Trading

Insider Ownership Percentage: 29.52%
Insider Buying (Last 12 Months): £10,157.70
Insider Selling (Last 12 Months): GBX 0

Oncimmune Insider Trading History Chart

This chart shows the insider buying and selling history at Oncimmune by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Oncimmune Share Price & Price History

Current Price: GBX 27.10
Price Change: Price Increase of +1.1 (4.23%)
As of 12/1/2023 01:00 AM ET

This chart shows the closing price history over time for ONC up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
Check out this training for the full story!

Oncimmune Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/5/2023Adam HillInsiderBuy48,370GBX 21£10,157.70
9/21/2022Adam HillInsiderBuy8,005GBX 62£4,963.10
3/7/2022Adam HillInsiderBuy7,533GBX 133£10,018.89
12/23/2021Adam HillInsiderBuy5,669GBX 168£9,523.92
12/21/2021Adam HillInsiderBuy5,988GBX 167£9,999.96
1/11/2021Cheung ToInsiderSell40,000GBX 185£74,000
1/8/2021Cheung ToInsiderSell10,000GBX 185£18,500
1/5/2021Cheung ToInsiderSell50,000GBX 175£87,500
12/17/2020Adam HillInsiderBuy5,764GBX 173£9,971.72
See Full Table

SEC Filings (Institutional Ownership Changes) for Oncimmune (LON:ONC)

37.88% of Oncimmune stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Oncimmune logo
Oncimmune Holdings plc develops and commercializes technologies that enable cancer diagnosis in the United Kingdom, North America, Europe, and internationally. It offers EarlyCDT-Lung, a immunodiagnostic test for detecting and identifying lung cancer. The company also develops SeroTag, a platform that is used to discover and validate biomarkers for stratifying patients in multiple cancer indications, infectious diseases, and with various autoimmune diseases; and NavigAID, a disease-specific characterization panel. Oncimmune Holdings plc has a collaboration with Siemens Healthineers AG. Oncimmune Holdings plc was incorporated in 2015 and is based in Leeds, the United Kingdom.
Read More on Oncimmune

Today's Range

Now: GBX 27.10
Low: 25.20
High: 27.38

50 Day Range

MA: GBX 18.04
Low: 15.01
High: 28.40

52 Week Range

Now: GBX 27.10
Low: 13
High: 73.71


139,493 shs

Average Volume

111,424 shs

Market Capitalization

£20.09 million

P/E Ratio


Dividend Yield




Who are the company insiders with the largest holdings of Oncimmune?

Oncimmune's top insider shareholders include:
  1. Adam Hill (Insider)
Learn More about top insider investors at Oncimmune.